Posted by Michael Wonder on 03 Mar 2021
On Target Laboratories announces U.S. FDA acceptance and priority review of new drug application for pafolacianine sodium injection for identification of ovarian cancer during surgery
3 March 2021 - On Target Laboratories today announced that the U.S. FDA has accepted its new drug application for priority review for pafolacianine sodium injection as an adjunct for identifying ovarian cancer during surgery.
Pafolacianine sodium injection is a novel molecule which is shown to bind to folate receptors and illuminate intra-operatively under near-infrared light, serving as an adjunct to provide greater certainty in a complete resection. It is administered via standard intravenous injection in as little as one hour before surgery.
